P112: ENERGIZE AND ENERGIZE-T: TWO PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDIES OF MITAPIVAT IN ADULTS WITH NON--TRANSFUSION-DEPENDENT OR TRANSFUSION-DEPENDENT ALPHA- OR BETA-THALASSEMIA

Documenti analoghi

• IMPROVEMENTS IN FATIGUE AND 6-MINUTE WALK TEST IN ADULTS WITH ALPHA- OR BETA-NON–TRANSFUSION-DEPENDENT THALASSEMIA: THE PHASE 3 ENERGIZE TRIAL OF MITAPIVAT
  di: KH Kuo, et al.
  Pubblicazione: (2024-10-01)
• P112: ENERGIZE AND ENERGIZE-T: TWO PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDIES OF MITAPIVAT IN ADULTS WITH NON--TRANSFUSION-DEPENDENT OR TRANSFUSION-DEPENDENT ALPHA- OR BETA-THALASSEMIA
  di: K Kuo, et al.
  Pubblicazione: (2022-01-01)
• Luspatercept versus mitapivat for non‐transfusion‐dependent β‐thalassemia: Dare to compare?
  di: Khaled M. Musallam, et al.
  Pubblicazione: (2025-07-01)
• Profile of Luspatercept in the Treatment of Anemia in Adults with Non-Transfusion-Dependent β-Thalassemia (NTDT): Design, Development and Potential Place in Therapy
  di: Musallam KM, et al.
  Pubblicazione: (2023-05-01)
• Luspatercept for transfusion-dependent β-thalassemia: time to get real
  di: Khaled M. Musallam, et al.
  Pubblicazione: (2023-08-01)